Andrew J. Reason

A number of new monoclonal antibody products and monoclonal antibody biosimilars are in development, all require extensive characterization to obtain the necessary approvals for clinical trials and eventually marketing approval.

The author describes techniques that can be used to provide the analytical data required by ICH Q6B for characterization of monoclonal antibodies.